Lutetium-177 Dotatate (Lutathera)
PeptideLutetium-177 dotatate is a radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT). FDA-approved 2018 for SSTR-positive GEP-NETs. NETTER-1 Phase 3: 65.2% PFS at 20 months vs 10.8% control. 79% reduction in disease progression/death risk. Median OS 48 months vs 36.3 months. First radiopharmaceutical for NETs.
Quick Answer
What it is
Lutetium-177 dotatate is a radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT). FDA-approved 2018 for SSTR-positive GEP-NETs.
Key findings
- Grade A: Progression-Free Survival (Neuroendocrine Tumors)
- Grade A: Overall Survival (Neuroendocrine Tumors)
- Grade A: Objective Response Rate (Neuroendocrine Tumors)
Safety
- 79% reduction in disease progression/death risk.
- 79% reduction in progression/death risk.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Lutetium-177 Dotatate (Lutathera)
Quick Facts: Lutetium-177 Dotatate (Lutathera)
- Best Evidence:Grade A
- Conditions Studied:1
- Research Outcomes:10
- Grade A Findings:4
- Grade B Findings:2
- Key Effect:Neuroendocrine Tumors
Detailed Outcomes
Evidence by Condition
Research Citations (40)
Related Peptides
Octreotide (Sandostatin)
Peptide1 shared condition · 13 outcomes
Octreotide is a synthetic octapeptide analog of somatostatin with prolonged action. FDA-approved in 1988, it is available as immediate-release injection and long-acting repeatable (LAR) formulation. Primary indications include acromegaly, carcinoid syndrome, and neuroendocrine tumors. The PROMID trial demonstrated significant antiproliferative effects in midgut neuroendocrine tumors, and multiple trials confirm efficacy for GH/IGF-1 suppression in acromegaly.
Lanreotide (Somatuline)
Peptide1 shared condition · 14 outcomes
Lanreotide is a long-acting synthetic octapeptide analog of somatostatin, FDA-approved for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The landmark CLARINET trial demonstrated 53% reduction in disease progression risk in metastatic GEP-NETs. Available as an extended-release depot formulation (Somatuline Depot) for once-monthly injection.